Company

Announcement on donations to support the fight against the new coronavirus pneumonia epidemic

Announcement on donations to support the fight against the new coronavirus pneumonia epidemic

Jul 02, 2020
By hqt

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

1. Overview of donations

Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as "the company") has effectively fulfilled the social responsibilities of listed companies, helping to prevent and control pneumonia caused by new coronaviruses. While doing its own prevention and control work, on February 2, 2020, the company used its own funds to donate 1 million yuan to the epidemic areas in Hubei and other regions through the Shenzhen Red Cross.

According to the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Articles of Association" and other relevant regulations, this donation does not constitute a connected transaction and does not need to be submitted to the company's board of directors and shareholders' general meeting for consideration. It does not constitute a major asset restructuring as prescribed by the China Securities Regulatory Commission's "Management Measures for Major Asset Restructuring of Listed Companies." And does not require approval from other relevant departments.

2. The impact of this donation on the company

The company's external donations are to support the fight against New Coronary Pneumonia and contribute to the prevention and control of New Coronavirus. It meets the requirements of the company's active commitment to social responsibility and is conducive to enhancing the company's social image. This time the external donation funds come from the company's own funds, and will not have a significant impact on the company's current and future operating performance, nor will it have a significant impact on the interests of investors.

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 3, 2020

Continue Reading
Voluntary Announcement on New Coronary Pneumonia Related Products

Voluntary Announcement on New Coronary Pneumonia Related Products

Jul 02, 2020
By hqt

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

I. Overview

1. Faced with the prevention and control of pneumonia caused by new coronavirus infection, Liyin Precision is acting.

Liyin Precision Medical Products (Shanghai) Co., Ltd. (hereinafter referred to as "Liyin Precision") is a holding subsidiary of Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as "Changhong Technology" or "Company") and is a research and development company. High-tech enterprises that mainly produce and sell medical device products. Established R&D and innovation centers including central laboratories and test centers, etc., and gradually formed six series of products including specimen collection systems, human-assisted reproductive systems, POCT reagents, sample processing systems, genetic testing reagents and consumables, and laboratory consumables. The mainline of the emerging medical device industry base.

With the rapid spread of the new coronavirus pneumonia epidemic (2019-nCoV), which poses a huge threat to the life and health of the Chinese people, Liyin Precision immediately launched an emergency response mechanism for the epidemic, paying attention to the progress of the disease and organizing The company's R&D, production, quality, logistics, and other departments started construction ahead of schedule to fully prepare for the production of four epidemic-related products. According to the "Notice of the Shanghai Municipal People's Government on Delaying the Resumption of Enterprises and Development of Schools in this Municipality", Liyin Precision actively responded to the spirit and requirements of the national epidemic prevention work and began normal work on February 10, 2020. At that time, the company's internal work arrangements are as follows:

  • For single-use virus sampling tubes, blood collection tubes for nucleic acid detection, biosafety centrifuges, and automatic vacuum blood collection tube sealing machines, priority is given to the production of four types of products related to the recent epidemic.
  • In response to the epidemic situation in Hubei Province, the company will fully cooperate and coordinate various resources to give priority to the production and delivery of orders from customers in Hubei. The company and colleagues in Hubei overcame difficulties together and fought against the epidemic.
  • At present, the company's sales department and marketing department staff have been working online at home, and our staff can be contacted on QQ, WeChat, and telephone.

2. Facing the prevention and control of pneumonia caused by new coronavirus infection, Boomingshing is taking action.

Shenzhen Boomingshing Medical Device Co., Ltd. (hereinafter referred to as "Boomingshing") is a wholly-owned subsidiary of Changhong Technology. It is mainly engaged in the design, development, and production of medical consumables and medical devices, medical tests, and basic equipment and appliances. Processing and sales, mainly for the global market to provide gene products full industry chain consumables, assisted reproductive consumables and reagents, life science laboratory consumables, IVD diagnostic consumables and reagents, special equipment manufacturing products and services.

In the fight against the new pneumonia epidemic of the new coronavirus in 2020, Boomingshing is currently mainly Shenzhen Huada Gene Co., Ltd. (hereinafter referred to as "Huada Gene"), Shenzhen Mindray Biomedical Electronics Co., Ltd. (hereinafter referred to as "Mindray Medical") ") and other customers to provide matching kits and consumable products.

The new coronavirus 2019-nCoV nucleic acid detection kit is a rapid detection kit based on RT-PCR technology and a detection kit based on metagenomic sequencing. Combining the above two detection methods, the 2019-nCoV virus detection can be covered faster and more comprehensively, and the mutations that may occur during the spread of the new coronavirus are monitored. In fact, the kit is the top priority for the diagnosis of new coronavirus. For the detection of the new coronavirus, the most important method at present is to detect whether there is the viral genetic material in humans (sputum, blood, alveolar lavage fluid), so as to confirm whether it is infected by the virus.

As a manufacturer of new coronavirus detection kit supporting products, Boomingshing urgently organized a 65-person team to rush production 24 hours a day and 24 hours after receiving the supply request of Huada Gene on January 30, 2020. The shifting work system, shouldering the mission of the enterprise, satisfies the needs of customers and realizes a daily output of about 28,500 pieces of new coronavirus detection kit supporting products. Boomingshing actively responded to the national epidemic prevention and control spirit and requirements and started construction on February 1, 2020, in advance, giving priority to the research and development and production of the following epidemic-related products.

  • Related consumables using Huada gene DNBSEQ-T7 sequencing system and new coronavirus detection kit;
  • Use the chemiluminescent reaction cup of Mindray Medical Biomedical Biochemical Testing;
  • Blood collection tubes and free DNA tubes for blood testing;
  • 96-well storage plate for gene sequencing.

This product is mainly used for diagnosis, sample collection, and sequencing in epidemic prevention work.

II. Introduce products related to new coronary pneumonia

1. A disposable virus sampling tube

The current new coronavirus is an RNA virus. After the samples are collected, incorrect storage or transportation may cause some nucleic acids to degrade and affect the test results. In addition, unactivated virus samples are likely to cause operator and indirect infection. For the laboratory, the safety level is high; and use existing nucleic acid detection kits, professional specimen collection tools should be used.

The single-use virus sampling tube is used for the collection and transportation of clinical influenza, new coronavirus, avian influenza (such as H7N9), hand-foot-mouth virus, measles, and other virus specimens, as well as mycoplasma, ureaplasma and chlamydia specimens. With the launch of new coronavirus detection reagents and general screening, the demand for single-use virus sampling tubes has increased significantly. In response to the production of products in short supply during the epidemic period, the company has increased its personnel into production during the holidays, and it can be supplied in large quantities one after another.

2. One-time blood collection tube for nucleic acid detection

Labtub® disposable blood collection tubes for nucleic acid detection (referred to as "nucleic acid detection tubes") are specially designed and manufactured for nucleic acid detection, mainly used in blood collection and supply institutions (blood stations, blood centers) and hospitals for venous blood samples for nucleic acid detection Collection, transportation, and storage, as well as pre-treatment of specimen analysis, to meet the clinical nucleic acid amplification test and clinical molecular diagnostic test methods to quickly prepare undiluted plasma specimens.

  • It is produced under pure purification conditions, and the possible pollution is minimized during the production process, effectively reducing the impact of possible carry-over pollution on the experiment.
  • The inner wall of the vacuum blood collection tube is treated with DEPC, the finished product is sterilized by Co60 irradiation, and the sterility guarantee level can reach 10-6, which can completely eliminate the effect of RNase on the experiment.
  • The application of unique additive technology will not affect the activity of the Taq enzyme in the nucleic acid detection experiment, and can effectively eliminate the interference of the hemoglobin in the red blood cell on the nucleic acid detection experiment.

In this new coronary pneumonia, the company's nucleic acid test tube can ensure the accuracy of the blood nucleic acid test results of the new coronavirus. To support epidemic prevention, the company has stocked hundreds of thousands of products.

3. Biosafety centrifuge and automatic vacuum blood collection tube sealing machine

Transmission through the respiratory tract droplets is the main transmission route for 2019-nCoV, and may also be transmitted through contact and aerosol (aerosol). An aerosol is a dispersion system in which solid or liquid particles are suspended in an inverse gas, and the particle diameter is between 0.001 and 100 μm. Medical laboratory and other personnel mainly contact patients' blood, urine, feces, and other samples, which can produce an aerosol. It can effectively eliminate aerosol pollution and avoid the biological contamination of medical personnel and cross-contamination between specimens by aerosol during the uncapping of blood collection tubes.

a. Biosafety centrifuge

Product use: Vacuum blood collection tube (specimen) centrifugal uncap; ordinary specimen centrifugation.

Product advantages: It can prevent aerosol pollution; the speed and centrifuge time of the centrifuge can be set freely, and the centrifugal force can be directly converted and displayed.

b. Automatic vacuum blood collection tube sealing machine

The automatic sealing machine introduced by Liyin Precision for the vacuum storage of blood collection tubes after the analysis of specimens in medical laboratories makes the post-processing of specimens safer, more convenient and more convenient, and is an ideal choice for laboratory safety and quality control.

The product has the following characteristics:

Each sample is sealed independently, so blood samples will not cross-contaminate when stored in the refrigerator. Maintain the originality of the specimen to the greatest extent to ensure the safety of the specimen and the safety of the personnel; discard the previous ordinary cling film cover or manually prevent the sealing method, use automatic machine sealing and stoppering, and the rubber stopper is pressed by the robot. It is suitable for various instrument tube racks without manual sample transfer.

4. Gene storage board

The product has the following characteristics:

Suitable for storage of most polar organic solutions, acidic and alkaline solutions, and other laboratory solutions; suitable for biological fields, such as PCE, RIA, EIA, cell culture, DNA testing, etc.

5. One-time use of vacuum blood collection tube

Scope of application: For the collection, storage, transport, and pretreatment of venous blood samples in clinical laboratories.

III Company performance and risk tips

Since this new coronary pneumonia occurred, sales of the company's kits and other epidemic-related products have increased compared with the same period last year. It is estimated that the subsequent sales revenue will change according to the development of the epidemic. Specific financial data will be disclosed in the 2020 periodic report.

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 6, 2020

Continue Reading
Announcement on the completion of the industrial and commercial change registration of wholly-owned subsidiaries

Announcement on the completion of the industrial and commercial change registration of wholly-owned subsidiaries

Jul 02, 2020
By hqt

All members of the company and the board of directors guarantee that the content of information disclosure is true, accurate, and complete without false records, misleading statements, or major omissions.

Shenzhen Changhong Technology Co., Ltd. (hereinafter referred to as the "Company") received a notice from the wholly-owned subsidiary Shenzhen Boomingshing Medical Device Co., Ltd. (hereinafter referred to as "Boomingshing"), and actively responded to the call of the national and local governments to take effective actions To support the epidemic prevention of new coronaviruses, the company's business scope will be adjusted accordingly, and "production and management of masks and forehead guns" will be added.

At present, the registration procedures for industrial and commercial change (registration) have been completed and the "Business License" issued by the Shenzhen Municipal Market Supervision Administration has been obtained. The main information is as follows:

Unified Social Credit Code: 91440300552122647A

Company Name: Shenzhen Boomingshing Medical Device Co., Ltd.

Type: Limited liability company (wholly owned by the legal person)

Legal representative: Li Huanchang

Date of establishment: March 11, 2010

Address: Floor 1 to 3, No. 4 Plant, Fuxingda Industrial Park, East Lanzhu Road, Pingshan New District, Shenzhen

Business period: Sustainable operation

Business Scope: Class I (Class I) medical consumables and medical devices, Class II 6841 medical testing and the design and development, production, processing, and sales of basic equipment and appliances, production and operation of masks and forehead guns; digital product accessories, production, processing, and sale of plastic products; import and export of goods, import and export of technology (articles prohibited by laws and administrative regulations; articles restricted by laws and administrative regulations must be licensed before they can operate). Engaged in Class II medical testing and sales of basic equipment; Class II and Class III injection puncture instruments, medical polymer materials and products, medical hygiene materials, and dressings. "

Special announcement!

Board of Directors of Shenzhen Changhong Technology Co., Ltd.

February 19, 2020

Continue Reading